Crossmark

Incorporating Patient Needs and Perspectives in Additional Risk Minimization Measures and Other Pharmacovigilance Deliverables - A Framework and Implementation Roadmap

Crossref DOI link: https://doi.org/10.1007/s43441-025-00844-5

Published Online: 2025-07-25

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Smeding, Linda

Massouh, Robert

Moyo, Farai

Metcalf, Marilyn

Altimari, Shannon

Edle von Dall’Armi, Ekaterina

Formenti, Elisa
Funding

Funding for this research was provided by:

GSK (N/A)
License Information

Text and Data Mining valid from 2025-07-25

Version of Record valid from 2025-07-25
More Information

Article History

Received: 7 March 2025

Accepted: 17 July 2025

First Online: 25 July 2025

Declarations

:

: MM declares stock or stock options from Janssen (Centocor). RM declares stock from Pfizer. All authors are employed by GSK. LS, RM, FM, MM, and SA hold financial equities in GSK. The authors declare no other financial or non-financial relationships.

Document is current

Any future updates will be listed below